Harvard format – short version

CURRICULUM VITAE

Name:	**Arcangela De Nicolo, M.D., Ph.D.**
Work address:	Veneto Institute of Oncology IOV-IRCCS via Gattamelata 64 35128 Padua (PD) Italy
E-mail:	arcangela.denicolo@iov.veneto.it
Citizenship:	Italian
Languages:	Italian (native), English (full professional proficiency), Spanish (elementary proficiency)

Education

2003	***Ph.D.***, Oncology and Surgical Oncology **University of Padua**, Padua, Italy *Thesis: Hereditary breast/ovarian cancer syndrome*
2000	***Certificate of Advanced Study Course***, Clinical and Experimental Oncology **University of Bari**, Bari, Italy
1998	***M.D.*** *summa cum laude* **University of Bari**, Bari, Italy

Advanced Curriculum Compendium

2010	***Certificate*** (pass)/Research Synthesis and Meta-Analysis in Public Health and Clinical Medicine **Harvard T.H. Chan School of Public Health**, Boston, MA, USA

Faculty Academic Appointments (Research and/or Teaching)

2016-	***Adjunct Faculty***/Ph.D. Course in Clinical and Experimental Oncology and Immunology/Genetics and Bioinformatics Analyses **University of Padua**, Padua, Italy
2009-2013	***Faculty (Instructor in Medicine)***/Departments of Cancer Biology and Medicine **Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women's Hospital**, Boston, MA, USA

Licensure and Certification

1999	Enrollment in the Italian Registry of Medical Doctors, Surgeons, and Dentists (#11623), District of Bari
1999	Italian Medical License

Research and Clinical Experience

2016-	***Staff Member***/Familial Cancer Clinic, Genetic Counseling and Melanoma Risk-Assessment Service **Veneto Institute of Oncology IOV-IRCCS**, Padua, Italy
2016-	***Investigator***/Cancer Genomics Program **Veneto Institute of Oncology IOV-IRCCS**, Padua, Italy
12/2015	***Collaborating Scientist***/Immunology and Molecular Oncology Unit **Veneto Institute of Oncology IOV-IRCCS**, Padua, Italy
2013-2015	***Guest Scientist***/Department of Biological Chemistry and Molecular Pharmacology **Harvard Medical School**, Boston, MA, USA
2011-2013	***Clinical Observer***/Breast Oncology Center and Center for Cancer Genetics and Prevention/Susan F. Smith Center for Women's Cancers **Dana-Farber Cancer Institute**, Boston, MA, USA
2009-2013	***Instructor in Medicine***/Departments of Medicine and Cancer Biology **Harvard Medical School/Dana-Farber Cancer Institute/Brigham and Women's Hospital**, Boston, MA, USA
2003-2009	***Research Fellow in Genetics***/Departments of Cancer Biology and Genetics **Dana-Farber Cancer Institute/Harvard Medical School**, Boston, MA, USA
2002	***Visiting Ph.D. Student***/Departments of Cancer Biology and Genetics **Dana-Farber Cancer Institute/Harvard Medical School**, Boston, MA, USA
1999-2002	***Ph.D. Student***/Department of Oncology and Surgical Sciences **University of Padua**, Padua, Italy

Mentoring/Supervisory Responsibilities and Committee Service

2018-	***Erasmus Exchange Program, Student Supervisor***/School of Medicine **University of Padua**, Padua, Italy
2018- 2000-2001	***Thesis Supervisor***/School of Medicine **University of Padua**, Padua, Italy
2019- 2016-2018	***Ph.D. Thesis Co-Supervisor***/Ph.D. Course in Clinical and Experimental Oncology and Immunology **University of Padua**, Padua, Italy
04/2016	***External Committee Member***/International Ph.D. Course in Molecular Medicine **Vita-Salute San Raffaele University**, Milan, Italy

Referee Activities

Editorial Activities (*ad hoc* Reviewer): Breast Cancer Research and Treatment, Cancer Epidemiology, Biomarkers and Prevention, Clinical Cancer Research, Frontiers in Oncology, JCO Precision Oncology, Mutation Research; **Grant Review Activities (International *ad hoc* Reviewer):** Italian Ministry of Health.

Membership in Scientific Societies

International: European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Association for Cancer Research (EACR), American Association for Cancer Research (AACR); **National:** Società Italiana di Genetica Umana (SIGU), Intergruppo Melanoma Italiano (IMI).

Honors, Awards, and Fellowships

2018	**Science Signaling**/Cover Story (volume 11, issue 543)
2014	**EMBO Journal**/Prize for Outstanding Poster
2014	**Molecular Systems Biology (EMBO Press)**/Poster of the Day Award
2009	**American-Italian Cancer Foundation (AICF)**/Best Paper Submitted Award
2009	**New York University (NYU)**/Travel Grant
2003-2004	**International Agency for Research on Cancer (IARC)-World Health Organization (WHO)**/Fellowship for Training in Cancer Research *Analysis of the X chromosome gene expression events after loss of BRCA1 function*
2002-2003	**Fondazione Italiana per la Ricerca sul Cancro (FIRC)**/Leonino Fontana and Maria Lionello Fellowship for Cancer Research Abroad *Functional characterization of the BRCA proteins*
2002	**University of Padua School of Medicine**/Exchange Travel Grant
1999-2002	**Italian Ministry of Education, University and Research (MIUR)**/Ph.D. Fellowship
1992	**Firestone**/Firestone Best Student Award
1991	**Nardone Foundation**/Nardone Merit Award

Grants

Principal Investigator: Susan G. Komen for the Cure/PDF0601163 (2006-2009), *X chromosome contribution to basal-like breast cancers.*

Co-principal Investigator (Principal Investigator: C. Menin)**: Veneto Institute of Oncology IOV-IRCCS**/Intramural "5x1000" Grant (2018-ongoing), *Genomic copy number variation and TERT promoter mutation analyses as tools to predict the response to targeted therapy in BRAF-mutated metastatic melanoma patients.*

Collaborator: University of Padua/prot. BIRD168075 (2016-2018), *Germline polymorphisms of candidate genes as predictors of risk and prognosis in patients with cutaneous melanoma and soft tissue sarcomas;* **Italian Ministry of University, Scientific Research, and Technology (MURST)**/PRIN prot. 2001064197_002 (2001-2002), *Hereditary breast and ovarian cancer:* a *multicentric study on biological and clinical parameters and management of at-risk individuals.*

Selected Peer-Reviewed Publications (Original Articles, Book Chapters, Review Essays)

1. Joukov V and **De Nicolo A**. The centrosome and the primary cilium: the yin and yang of a hybrid organelle. *Cells 2019;8(7):E701*. Review.

2. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo S, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Faust U, Felbor U, Feroce I, Fine M, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S,

Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, Lopez-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Pérez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C, KConFab Investigators, Lázaro C, **De Nicolo A**, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood analysis of *BRCA1* and *BRCA2* variants: An ENIGMA resource to support clinical variant classification. *Hum Mutat 2019;40(9):1557-78*.

3. Stratigos AJ[*], Fargnoli MC[*], **De Nicolo A**[*], Peris K, Puig S, Soura E, Menin C, Calista D, Ghiorzo P, Mandalà M, Massi D, Rodolfo M, Del Regno L, Stefanaki I, Gogas H, Bataille V, Tucker MA, Whiteman D, Nagore E, Landi MT. MelanoQ: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the MelaNostrum Consortium. *J Eur Acad Dermatol Venereol 2018;32(12):2134-41*. [*]Equal contribution and shared first authorship.

4. Nielsen SM, Eccles DM, Romero I, Al-Mulla F, Biancolella M, Blok R, Caligo MA, Calvello M, Capone GL, Cavalli P, Chan TLC, Claes KBM, Cortesi L, Couch FJ, de la Hoya M, De Toffol S, Diez O, Domchek SM, Eeles R, Efremidis A, Fostira F, Goldgar D, Hadjisavvas M, Hansen TvO, Hirasawa A, Houdayer C, Kleiblova P, Krieger S, Lázaro C, Louizidou M, Manoukian S, Mensenkamp AR, Moghadasi S, Monteiro AN, Mori L, Morrow A, Naldi N, Nielsen HR, Olopade OI, Pachter NS, Palmero EI, Pedersen IS, Piane M, Puzzo M, Robson M, Rossing M, Sini MC, Solano A, Soukupova J, Tedaldi G, Teixeira M, Thomassen M, Tibiletti MG, Toland A, Törngren T, Vaccari E, Varesco L, Vega A, Wallis Y, Wappenschmidt B, Weitzel J, Spurdle AB, **De Nicolo A**, Gómez-García EB. Genetic testing and clinical management practices for variants in non-*BRCA1/2* breast (and breast/ovarian) cancer susceptibility genes: an international survey by the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. *JCO Precis Oncol 2018;2. doi: 10.1200/PO.18.00091. Epub 2018 Oct 26.*

5. Gu F, Chen TH, Pfeiffer RM, Fargnoli MC, Calista D, Ghiorzo P, Peris K, Puig S, Menin C, **De Nicolo A**, Rodolfo M, Pellegrini C, Pastorino L, Evangelou E, Zhang T, Hua X, Della Valle CT, Bishop DT, MacGregor S, Iles MI, Law MH, Cust A, Brown KM, Stratigos AJ, Nagore E, Chanock S, Shi J, Melanoma Meta-Analysis Consortium, MelaNostrum Consortium, Landi MT. Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. *Hum Mol Genet 2018;27(23):4145-56.*

6. Joukov V and **De Nicolo A**. Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis. *Sci Signal 2018;11(543)*. Review. •*Cover story*.

7. Stagni C, Zamuner C, Elefanti L, Zanin T, Del Bianco P, Sommariva A, Fabozzi A, Pigozzo J, Mocellin S, Montesco MC, Chiarion-Sileni V, **De Nicolo A**[§], Menin C[§]. BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors. *Mol Cancer Ther 2018;17(6):1332-40.* [§]Shared senior authorship.

8. Joukov V, Walter JC, **De Nicolo A**. Assays to study mitotic centrosome and spindle pole assembly and regulation. *Methods Mol Biol (The Mitotic Spindle) 2016;1413:207-35*. Chapter in a book.

9. Joukov V, Walter JC, **De Nicolo A**. The Cep192-organized Aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly. *Mol Cell 2014;55(4):578-91*.

10. Cortesi L[*§], **De Nicolo A**[*§], Medici V, Marino M, Turchetti D, Pradella LM, Rossi G, Parisini E, Federico M. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV

motif of the first BRCT repeat. *Breast Cancer Res Treat 2012;134(1):435-41*. *Equal contribution and shared first authorship. §Corresponding authors.

11. Joukov V, **De Nicolo A**, Rodriguez A, Walter JC, Livingston DM. Centrosomal protein of 192 kDa (Cep192) promotes centrosome-driven spindle assembly by engaging in organelle-specific Aurora A activation. *Proc Natl Acad Sci U S A 2010;107(49):21022-7*.

12. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, **De Nicolo A**, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. *J Clin Oncol 2010;28(7):1145-53*.

13. **De Nicolo A**§, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, Caligo MA, Vidal M, Cusick ME, Garber JE. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. *Cancer Res 2009;69(17):7030-7*. §Corresponding author.

14. **De Nicolo A***, Tancredi M*, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G, Drapkin R, Caligo MA. A novel breast cancer-associated *BRIP1* (*FANCJ/BACH1*) germ-line mutation impairs protein stability and function. *Clin Cancer Res 2008;14(14):4672-80*. *Equal contribution and shared first authorship. •<u>*Featured in Clin Cancer Res 2008;14(14):Highlights*</u>.

15. Richardson AL, Wang ZC, **De Nicolo A**, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell 2006;9(2):121-32*.

16. Aretini P, D'Andrea E, Pasini B, Viel A, Mariani Costantini R, Cortesi L, Ricevuto E, Agata S, Bisegna R, Boiocchi M, Caligo MA, Chieco-Bianchi L, Cipollini G, Crucianelli R, D'Amico C, Federico M, Ghimenti C, De Giacomi C, **De Nicolo A**, Della Puppa L, Ferrari S, Ficorella C, Iandolo D, Manoukian S, Marchetti P, Marroni F, Menin C, Montagna M, Ottini L, Pensotti V, Pierotti M, Radice P, Santarosa M, Silingardi V, Turchetti D, Bevilacqua G, Presciuttini S. Different expressivity of *BRCA1* and *BRCA2*: analysis of 179 Italian pedigrees with identified mutation. *Breast Cancer Res Treat 2003;81(1):71-9*.

17. Montagna M, Dalla Palma M, Menin C, Agata S, **De Nicolo A**, Chieco-Bianchi L, D'Andrea E. Genomic rearrangements account for more than one-third of the *BRCA1* mutations in northern Italian breast/ovarian cancer families. *Hum Mol Genet 2003;12(9):1055-61*.

18. Agata S*, **De Nicolo A***, Chieco-Bianchi L, D'Andrea E, Menin C, Montagna M. The *BRCA2* sequence variant IVS19+1G>A leads to an aberrant transcript lacking exon 19. *Cancer Genet Cytogenet 2003;141(2):175-6*. *Equal contribution and shared first authorship.

19. Motta G, Vianello F, Menin C, **De Nicolo A**, Agata S, Altavilla G, Pietrogrande F, Girolami A. Hepatosplenic γδ T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans' syndrome). *Am J Hematol 2002;69(4):272-6*.

20. Montagna M, Agata S, **De Nicolo A**, Menin C, Sordi G, Chieco-Bianchi L, D'Andrea E. Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis. *Int J Cancer 2002;98(5):732-6*.

21. Nicoletto MO, Donach M, **De Nicolo A**, Artioli G, Banna G, Monfardini S. BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling. *Cancer Treat Rev 2001;27(5):295-304*. Review.

22. Menin C, Banna GL, De Salvo G, Lazzarotto V, **De Nicolo A**, Agata S, Montagna M, Sordi G, Nicoletto O, Chieco-Bianchi L, D'Andrea E. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. *Cancer Lett 2001;168(1):31-6*.

Padua, October 28, 2019